This is a working overview of Dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-12. Anything still debated is marked as such rather than presented as settled.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Starmer says he has taken account of whether it would be right "to impose a further burden on the taxpayer". MSPs vote unanimously in favour of plans to ban dual mandates. Following an external review into the use of messaging services, Scotland's Deputy First Minister, Kate Forbes announces that Scottish Government ministers and staff will be banned from using WhatsApp for official business. Former First Minister of Scotland Humza Yousaf announces he will step down as an MSP at the 2026 Scottish Parliament election. Democracy and Boundary Commission Cymru unveils the names of the 16 constituencies that will make up the enlarged Senedd from 2026, with all but four of them known by exclusively Welsh language names. The Welsh Conservatives reaffirm their commitment to devolution following a social media post by MS Joel James, who said he wanted to get "rid" of the Senedd; the post, in response to the announcement of the constituencies for the 2026 election, was swiftly deleted. Nigel Farage says that Reform UK are in "open negotiations" with US billionaire Elon Musk about him donating to the party after the pair met at Donald Trump's Mar-a-Lago estate in Florida. 18 December – Reform UK confirms that Craig Campbell, a party official in Scotland, has been removed from his post after revelations his family has links to Ulster Loyalists and has a relatives who was convicted of murdering a Celtic fan. Police are called to what is described as a heated meeting of Oldham Council.
C4H2N2O4 + GSH → C4H3N2O4• + GS• C4H3N2O4• + GSH → C4H4N2O4 + GS• C4H4N2O4 + O2 → C4H3N2O4• + O2•− + H+ C4H3N2O4• + O2 → C4H2N2O4 + O2•− + H+ Because it selectively kills the insulin-producing beta-cells found in the pancreas, alloxan is used to induce diabetes in laboratory animals. This occurs most likely because of selective uptake of the compound due to its structural similarity to glucose as well as the beta-cell's highly efficient uptake mechanism (GLUT2). In addition, alloxan has a high affinity to SH-containing cellular compounds and, as a result, reduces glutathione content. Furthermore, alloxan inhibits glucokinase, a SH-containing protein essential for insulin secretion induced by glucose. Most studies have shown that alloxan is not toxic to the human beta-cell, even in very high doses, probably because of differing glucose uptake mechanisms in humans and rodents. Alloxan is, however, toxic to the liver and the kidneys in high doses, as these are tissues where the GLUT2 transporter is expressed in humans. Streptozotocin
Projected to go undrafted by Sports Illustrated, who criticized his lack of "balance, body control and ability in space," Kuper was ranked as the No. 28 offensive guard available in the 2006 NFL draft. Kuper was eventually selected in the fifth round, 161st overall, by the Denver Broncos. He was the highest selected North Dakota lineman since Todd Thomas in 1981. Kuper started 79-of-90 games played (68 at right guard) while playing his entire eight-year NFL career with the Broncos. On June 4, 2010, the Broncos announced that they had signed Kuper to a five-year deal worth $25.5 million. The new contract made him the second-highest-paid offensive lineman in Broncos' history, second only to former left tackle Matt Lepsis. In 2010, the Denver Broncos announced that Kuper had been selected as co-captain of the Broncos offense, along with Kyle Orton and Daniel Graham. During the regular season finale in 2011 against the Kansas City Chiefs, Kuper suffered a gruesome broken ankle that ended his season. That season Kuper made the Pro Bowl, but withdrew due to the injury and needed surgery. A three-time captain, Kuper was recipient of the Ed Block Courage Award in 2012 as voted on by his teammates. Kuper retired on March 11, 2014.
4 HF + UO2 → UF4 + 2 H2O To extract plutonium, neutron-irradiated uranium is dissolved in nitric acid, and a reducing agent (FeSO4, or H2O2) is added to the resulting solution. This addition changes the oxidation state of plutonium from +6 to +4, while uranium remains in the form of uranyl nitrate (UO2(NO3)2). The solution is treated with a reducing agent and neutralized with ammonium carbonate to pH = 8 that results in precipitation of Pu4+ compounds. In another method, Pu4+ and UO2+2 are first extracted with tributyl phosphate, then reacted with hydrazine washing out the recovered plutonium. The major difficulty in separation of actinium is the similarity of its properties with those of lanthanum. Thus actinium is either synthesized in nuclear reactions from isotopes of radium or separated using ion-exchange procedures.
Sources: en.wikipedia.org
== Statements by Combatants' Presidents and Prime ministers == On 7 August, state-controlled Rossiya TV aired Abkhaz separatist leader Sergei Bagapsh, who said at a meeting of the Abkhaz National Security Council: "I have spoken to the president of South Ossetia. It has more or less stabilized now. A battalion from the North Caucasus District has entered the area." The phone conversation between Bagapsh and Kokoity had taken place on late 6 August. By the evening of 7 August, Bagapsh had ordered the Abkhaz armed forces to raise combat readiness. Pro-Georgian president of South Ossetia Dmitry Sanakoyev told Russian journalist Dmitry Steshin by 8 August 2008 that neither he nor the Georgian government needed the war and cited multi-billion Georgian investment into the development of South Ossetia as a proof that Georgia was not preparing the war. Prime Minister Lado Gurgenidze said on 8 August that South Ossetian separatists launched a deliberate attack on the Georgian civilians after Saakashvili's announcement of ceasefire and that 100-vehicle armed convoy had entered through the Roki Tunnel from Russia before the midnight. Gurgenidze said that the Georgian government had notified the command of the Russian peacekeepers that Georgia was forced to respond to the attack. On 11 August 2008, Georgian president Mikheil Saakashvili wrote that the war was provoked by the Kremlin and while Georgia was showing restraint, Russia escalated the conflict in South Ossetia.
Cave paintings from more than 3,500 years ago document burns and their management. The earliest Egyptian records on treating burns describes dressings prepared with milk from mothers of baby boys, and the 1500 BCE Edwin Smith Papyrus describes treatments using honey and the salve of resin. Many other treatments have been used over the ages, including the use of tea leaves by the Chinese documented to 600 BCE, pig fat and vinegar by Hippocrates documented to 400 BCE, and wine and myrrh by Celsus documented to the 1st century CE. French barber-surgeon Ambroise Paré was the first to describe different degrees of burns in the 1500s. Guillaume Dupuytren expanded these degrees into six different severities in 1832. The first hospital to treat burns opened in 1843 in London, England, and the development of modern burn care began in the late 1800s and early 1900s. During World War I, Henry D. Dakin and Alexis Carrel developed standards for the cleaning and disinfecting of burns and wounds using sodium hypochlorite solutions, which significantly reduced mortality. In the 1940s, the importance of early excision and skin grafting was acknowledged, and around the same time, fluid resuscitation and formulas to guide it were developed. In the 1970s, researchers demonstrated the significance of the hypermetabolic state that follows large burns. The "Evans formula", described in 1952, was the first burn resuscitation formula based on body weight and surface area (BSA) damaged.
=== United Kingdom === In Aberdeen, in 1964, a large-scale (>400 cases) outbreak of typhoid occurred, caused by contaminated corned beef which had been imported from Argentina. The corned beef was placed in cans and because the cooling plant had failed, cold river water from the Plate estuary was used to cool the cans. One of the cans had a defect and the meat inside was contaminated. That meat was then sliced using a meat slicer in a shop in Aberdeen, and a lack of machinery-cleaning led to the spreading of the contamination to other meats cut in the slicer. Those meats were eaten by people in Aberdeen who then became ill. Serious outbreaks of foodborne illness since the 1970s prompted key changes in UK food safety law. The outbreaks included the deaths of 19 patients in the Stanley Royd Hospital outbreak and the bovine spongiform encephalopathy (BSE, mad cow disease) outbreak identified in the 1980s. The deaths of 21 people in the 1996 Wishaw outbreak of E. coli O157 was a precursor to the establishment of the Food Standards Agency which, according to Tony Blair in the 1998 white paper A Force for Change Cm 3830, "would be powerful, open and dedicated to the interests of consumers". In May 2015, for the second year running, England's Food Standards Agency devoted its annual Food Safety Week to "The Chicken Challenge". The focus was on the handling of raw chicken in the home and in catering facilities in a drive to reduce the high levels of food poisoning from the campylobacter bacterium.
== Post summit == From 11 to 12 November 2025, the G7 Foreign Ministers' Meeting was held at Niagara-on-the-Lake, and joint statement was issued. The joint statement showed their consensus on Ukraine and Sudan, but stayed away from contentious issues like the US military strikes on boats in the Caribbean and trade. They are increasing the economic costs to Russia and exploring measures against those who finance Russia's war efforts. Also, they raised alarm over China's military buildup and reiterated their resolve to create an alternative to its dominance in critical mineral supplies, and reaffirmed the importance of a Free and Open Indo-Pacific based on the rule of law.
==== GSK–Pfizer joint venture ==== In December 2018, GSK announced that it, along with Pfizer, had reached an agreement to merge and combine their consumer healthcare divisions into a single entity. The combined entity would have sales of around £9.8 billion ($12.7 billion), with GSK maintaining a 68% controlling stake in the joint venture. Pfizer would own the remaining 32% shareholding. The deal builds on an earlier 2018 deal where GSK bought out Novartis' stake in the GSK-Novartis consumer healthcare joint business.
Sources: en.wikipedia.org
This way, it is possible to integrate any device by any manufacturer as long as they are controlled by a computer, which is often the case. Another important development in robotics which has important potential implications for laboratories is the arrival of robots that do not demand special training for their programming, like Baxter, the robot.
=== Europe === The prevalence of congenital corneal opacities (CCO) is estimated to be 3 in 100,000 newborns. This number increases to 6 in 100,000 if congenital glaucoma patients are included. A study of live births in Spain reported that corneal opacities accounted for 3.11% of congenital eye malformations (Bermejo et al, 1998). About 4% of keratoplasties done in the pediatric population in Denmark are due to congenital anomalies (Hovlykke et al, 2014).
=== Brand names === Propranolol was first marketed under the brand name Inderal, manufactured by ICI Pharmaceuticals (now AstraZeneca), in 1965. "Inderal" is a quasi-anagram of "Alderlin", the trade name of pronethalol (which propranolol replaced); both names are an homage to Alderley Park, the ICI headquarters where the drugs were first developed. Propranolol is also sold under the brand names Avlocardyl, Deralin, Dociton, Hemangeol, Inderalici, InnoPran XL, Indoblok, Sumial, Anaprilin, and Bedranol SR (Sandoz). In India, it is sold under brand names such as Ciplar and Ciplar LA by Cipla.
For 2026 and subsequent years, qualified overtime compensation must be reported on Form W-2, box 12, code TT. Employers must report all qualified overtime compensation without regard to the tax limit of $12,500 ($25,000 if married filing jointly). An employee who is actively engaged in the management of their employer and owns at least a 20-percent equity interest in it is not eligible to take the tax deduction. Overtime compensation is not excluded or exempt from gross income. Employers continue to be required to withhold income taxes, social security taxes, and Medicare taxes from workers' overtime pay. An employee is allowed, however, to give their employer an updated Form W-4 that includes their acticipated tax deduction for qualified overtime compensation in Step 4(b).
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.